The round was led by existing investor Anzu Partners with participation from Entegris and fellow existing investor RA Capital Management.
TeraPore will use the funding to launch its IsoBlock virus filter and expand the use of its core technology into new high value markets.
The company is developing a new generation of high-capacity, high-yield bioseparation solutions that enable controllable, consistent purification processes for the manufacturing of novel therapeutics and biologics. Unlike conventional filter technology, IsoBlock virus filters leverage TeraPore’s Intelligent Membrane platform, which features a tunable chemical structure and uniform nanoscale pore sizes that can tackle the most difficult separation challenges.
“As the pipeline for new biologics continues to rapidly increase, so does the need for more powerful and precise filtration technologies like ours that can improve the manufacturing process,” said Dr Rachel Dorin, CEO and co-founder of TeraPore Technologies. “We are glad to have the continued support of Anzu Partners and RA Capital Management and are excited to welcome Entegris as a new investor. Entegris brings deep technical expertise and can help accelerate the deployment of our technology into new contamination control applications.”
“We are pleased to contribute to the development of TeraPore as it enters the critical commercialization phase for their highly differentiated Intelligent Membrane platform,” said Olivier Blachier, senior vice president at Entegris. “We believe that this technology has a high potential to also address important nanofiltration challenges in a number of applications.”
Olivier Blachier, who leads business and new market development for Entegris, will also join the TeraPore board of directors along with Mani Krishnan, a seasoned expert in the filtration and biotechnology sector who held leadership roles at Millipore Sigma and Pall Corp.
